SB
SUPN icon

Suntrust Banks’s Supernus Pharmaceuticals SUPN Stock Holding History

Suntrust Banks’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-8,516
Closed -$339K – 1343
2017
Q4 		$339K Sell
8,516
-1,674
-16% -$66.1K ﹤0.01% 996
2017
Q3 		$407K Sell
10,190
-2,152
-17% -$93.1K ﹤0.01% 948
2017
Q2 		$532K Buy
12,342
+204
+2% +$7.26K ﹤0.01% 828
2017
Q1 		$380K Sell
12,138
-7,432
-38% -$199K ﹤0.01% 929
2016
Q4 		$493K Buy
19,570
+1,594
+9% +$35.6K ﹤0.01% 999
2016
Q3 		$443K Buy
17,976
+273
+2% +$6.18K ﹤0.01% 1008
2016
Q2 		$360K Buy
17,703
+1,017
+6% +$18K ﹤0.01% 1081
2016
Q1 		$253K Buy
+16,686
New +$218K ﹤0.01% 1214

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Suntrust Banks's SUPN Position: Q1 2018 in Review

Suntrust Banks sold out of Supernus Pharmaceuticals (SUPN) in Q1 2018, closing a stake of 8,516 shares — an estimated $339K sold.

Suntrust Banks first reported a position in SUPN in Q1 2016 and held it in 8 quarters. The position peaked at $532K in Q2 2017. 312 funds tracked by Wall St. Rank hold SUPN as of Q1 2018.

  • Suntrust Banks reported no remaining Supernus Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Suntrust Banks sold 8,516 Supernus Pharmaceuticals shares in Q1 2018, an estimated $339K.
  • Suntrust Banks first reported a position in Supernus Pharmaceuticals in Q1 2016 and held it in 8 quarters.
  • Suntrust Banks's Supernus Pharmaceuticals position peaked at $532K in Q2 2017.
  • 312 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2018.

Based on Suntrust Banks's 13F filing for Q1 2018, filed 14 May 2018.